ENDRA Life Sciences Inc.

NDRA

ENDRA Life Sciences Inc.

NDRA

Insider Sentiment (TTM):

Last Purchase:2024-08-27Last Sale:-Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:89,636Shares Outstanding:1,199,586Institutional Ownership Pct.:7.47%

Earnings Market Reaction:

Filing Date:2026-08-14Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Series A Convertible Preferred Stock	-	-	-	-	0	0	0	0	-0	0	0	0
Series B Convertible Preferred Stock	-	-	-	-	0	0	0	0	0	0	0	0
Assets
Series C Convertible Preferred Stock	-	-	-	-	0	0	0	0	0	0	0	0
Cash	-	0	1	1	-	-	3	-	-	-	-	-
Assets Current
Assets Current	6	1	1	1	2	2	3	5	7	1	3	6
Prepaid Expense Current	0	0	0	0	0	0	0	0	0	0	0	0
Cash And Cash Equivalents At Carrying Value	-	-	1	-	2	2	3	5	6	1	3	3
Assets Noncurrent
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	0	0	0
Inventory Net	-	-	0	-	-	-	0	3	3	3	3	3
Other Assets	-	-	-	-	0	0	0	0	0	0	0	0
Other Assets Noncurrent	0	0	0	0	-	-	0	-	-	-	-	-
Operating Lease Right Of Use Asset	0	0	0	0	1	1	1	0	0	0	0	0
Prepaid Expense Noncurrent	-	-	0	0	0	0	0	0	1	1	1	1
Crypto Asset Fair Value Current	2	2	2	-	-	-	-	-	-	-	-	-
Assets	8	3	4	2	3	3	4	8	10	5	7	8
Liabilities And Stockhold…
Short Term Borrowings	-	-	-	-	-	-	0	0	0	0	0	0
Accounts Payable And Accrued Liabilities Current	1	1	1	1	0	0	1	1	1	1	1	2
Liabilities Current
Liabilities Current	1	1	1	1	1	1	1	1	1	1	1	2
Long Term Debt
Long Term Debt	-	-	-	-	-	-	0	-	-	0	0	-
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Value	-	-	-	-	-	0	-	-	-	-	-	-
Contract With Customer Liability	-	-	-	-	0	0	-	1	-	-	-	-
Liabilities Noncurrent
Liabilities Noncurrent	1	1	1	1	1	1	1	1	0	0	0	0
Operating Lease Liability Noncurrent	0	0	0	0	-	-	0	0	0	0	0	0
Derivative Liabilities Noncurrent	1	0	0	1	-	-	1	-	-	-	-	-
Liabilities	2	2	2	2	1	1	2	2	1	1	1	2
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders Equity
Stockholders Equity	6	2	2	0	1	2	3	7	9	4	6	5
Additional Paid In Capital	118	114	113	107	107	106	106	106	106	98	98	96
Retained Earnings Accumulated Deficit	-112	-112	-110	-107	-106	-104	-103	-99	-97	-95	-92	-90
Preferred Class B	-	-	-	-	0	0	-	-	-	-	-	-
Liabilities And Stockholders Equity	8	3	4	2	3	3	4	8	10	5	7	8
Series A Preferred Stock	-	0	0	-0	0	0	0	0	-	0	-	-
Series B Preferred Stock	-	0	0	0	-	-	0	-	-	-	-	-
Series C Preferred Stock	-	0	0	0	0	0	0	-	-	-	-	-
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	1,000	1,000	1,000	20	20	20	1,000	20	1,000	80	20	80
Common Stock Shares Issued	1	1	1	1	1	1	1	1	55	11	6	8
Shares Outstanding	1	1	1	1	1	1	1	1	72	11	6	8
Preferred Stock Par Or Stated Value Per Share	-	-	-	-	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	-	-	-	-	10	10	10	10	10	10	10	10

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-16.24%	-6.53%	-6.93%	-	-	-	-	-	-	-	-	-
2025	4.67%	10.28%	50.78%	-3.83%	29.50%	18.24%	-11.04%	-35.97%	-43.28%	6.88%	17.42%	2.37%
2024	-65.17%	-68.62%	-73.10%	-89.53%	-92.51%	-89.85%	-18.98%	13.47%	-0.19%	-2.93%	-24.15%	-22.20%
2023	-	-	-	-	-	-	59.57%	55.32%	8.51%	-57.41%	-47.07%	-82.07%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	7.10	0.64	1.29	1.31	3.21	3.85	5.67	6.10	4.97	1.04	3.36	2.95
Quick Ratio	7.04	0.43	1.02	0.99	3.14	3.65	5.34	2.50	2.73	-1.30	0.23	1.54
Working Capital	4.80M	-298.77K	217.01K	248.40K	1.28M	1.61M	2.83M	4.15M	5.36M	53.82K	2.13M	4.23M
Leverage & Debt
Debt to Equity	0.26	0.92	0.71	10.46	0.91	0.81	0.74	0.27	0.16	0.37	0.19	0.46
Debt Ratio	0.21	0.48	0.41	0.91	0.48	0.45	0.42	0.21	0.14	0.27	0.16	0.32
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-2.39	-6.09	-8.93	-10.52	-12.22	-17.52	-56.94	-35.73	-	-	-2,766.85	-
Free Cash Flow Per Share TTM	-3.66	-4.18	-6.61	-6.70	-7.81	-11.80	-36.81	-32.84	-0.16	-0.84	-1.61	-1.25
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-32.50%	-25.24%	-38.93%	-9.20%	-8.36%	-1.26%	14.39%	-25.83%	-21.79%	-25.41%	-23.67%	-8.49%
EPS Growth (1Y)	-63.44%	-65.25%	-84.32%	-70.56%	6,981.50%	1,832.80%	3,260.29%	2,427.64%	-89.44%	-78.34%	-59.25%	587.23%
Valuation Metrics
P/E TTM	-1.19	-0.76	-0.51	-0.51	-0.29	-0.23	-0.11	-0.20	-983.45	-1,119.78	-2,189.44	-1,374.22
P/B TTM	1.12	3.12	1.58	23.90	1.71	1.30	0.49	0.26	1,045.91	2,995.58	3,892.26	3,144.52
Market Cap	7.06M	5.58M	3.57M	4.10M	2.52M	2.29M	1.27M	1.74M	9.41B	11.08B	22.03B	16.34B
Enterprise Value	1.52M	5.22M	2.80M	3.30M	708.47K	221.21K	-1.96M	-3.01M	9.40B	11.08B	22.02B	16.34B
Calculated Values
Free Cash Flow TTM	-4.84M	-5.01M	-5.20M	-5.10M	-5.60M	-6.58M	-7.44M	-8.10M	-9.05M	-9.22M	-9.58M	-10.53M
Net Debt	-5.54M	-356.46K	-762.37K	-794.04K	-1.81M	-2.06M	-3.23M	-4.75M	-6.40M	-1.13M	-2.81M	-3.31M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2024-08-27Purchase

Owner: Ubs, Group Ag

Title: -

Shares: 3,715

Price/Share: $0.55

Value: $2,043.25

Shares Owned: 146,012

Relationship: TenPercentOwner

Ownership: Indirect

2024-08-27Purchase

Owner: Ubs, Group Ag

Title: -

Shares: -

Price/Share: $0.00

Value: -

Shares Owned: 146,012

Relationship: Other

Ownership: Indirect

2023-05-18Purchase

Owner: Thornton, Michael Milos

Title: Chief Technology Officer

Shares: 15,000

Price/Share: $1.65

Value: $24,750.00

Shares Owned: 34,139

Relationship: Officer

Ownership: Direct

2023-05-02Purchase

Owner: Digiandomenico, Anthony

Title: -

Shares: 83,333

Price/Share: $1.20

Value: $99,999.60

Shares Owned: 102,434

Relationship: Director

Ownership: Direct

2022-12-09Purchase

Owner: Thornton, Michael Milos

Title: Chief Technology Officer

Shares: 1,500

Price/Share: $3.40

Value: $5,100.00

Shares Owned: 19,139

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2024-08-27	Ubs, Group Ag	TenPercentOwner	-	Indirect	Purchase	3,715	0.55	$2,043.25	146,012	4
2024-08-27	Ubs, Group Ag	Other	-	Indirect	Purchase	0	0.00	$0.00	146,012	4/A
2023-05-18	Thornton, Michael Milos	Officer	Chief Technology Officer	Direct	Purchase	15,000	1.65	$24,750.00	34,139	4
2023-05-02	Digiandomenico, Anthony	Director	-	Direct	Purchase	83,333	1.20	$99,999.60	102,434	4
2022-12-09	Thornton, Michael Milos	Officer	Chief Technology Officer	Direct	Purchase	1,500	3.40	$5,100.00	19,139	4
2022-11-23	Tokman, Alexander Y	Director	-	Direct	Purchase	10,000	0.17	$1,700.00	162,857	4
2022-08-22	Thornton, Michael Milos	Officer	Chief Technology Officer	Direct	Purchase	20,000	0.27	$5,400.00	352,775	4
2022-08-22	Tokman, Alexander Y	Director	-	Direct	Purchase	20,000	0.26	$5,200.00	152,857	4
2022-05-26	Thornton, Michael Milos	Officer	Chief Technology Officer	Direct	Purchase	25,000	0.21	$5,250.00	332,775	4
2022-05-18	Thornton, Michael Milos	Officer	Chief Technology Officer	Direct	Purchase	25,000	0.22	$5,500.00	307,775	4
2022-05-17	Michelon, Francois Roger	Director,Officer	Chief Executive Officer	Direct	Purchase	5,100	0.19	$969.00	97,191	4
2022-05-16	Tokman, Alexander Y	Director	-	Direct	Purchase	100,000	0.20	$20,000.00	132,857	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

7.47%

Inst. Shares: 89,636

Shares Outstanding: 1,199,586

2025-12-31

9.13%

Inst. Shares: 71,890

Shares Outstanding: 787,020

2025-09-30

1.72%

Inst. Shares: 13,086

Shares Outstanding: 761,218

2025-06-30

0.85%

Inst. Shares: 4,736

Shares Outstanding: 557,582

2025-03-31

0.20%

Inst. Shares: 1,134

Shares Outstanding: 557,582

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	89,636	1,199,586	7.47%
2025-12-31	71,890	787,020	9.13%
2025-09-30	13,086	761,218	1.72%
2025-06-30	4,736	557,582	0.85%
2025-03-31	1,134	557,582	0.20%
2024-12-31	112	202,106	0.06%
2024-09-30	74,529	246,816	30.20%
2024-06-30	471,253	246,816	190.93%
2024-03-31	229,351	10,914,447	2.10%
2023-12-31	130,285	5,937,000	2.19%
2023-09-30	129,536	8,411,777	1.54%
2023-06-30	168,357	7,481,603	2.25%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

ENDRA Life Sciences Inc. (NDRA) — SEC Financial Statements & Analysis

ENDRA Life Sciences Inc. (NDRA) is a electromedical & electrotherapeutic apparatus company, incorporated in DE. ENDRA Life Sciences Inc. trades on Nasdaq as: NDRA. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), ENDRA Life Sciences Inc. reported a Debt-to-Equity ratio of 0.26x, a Price-to-Book (P/B) ratio of 1.12x (TTM), at a market cap of $7.06M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.26x
P/B TTM: 1.12x
Market Cap: $7.06M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is ENDRA Life Sciences Inc. in?

ENDRA Life Sciences Inc. (NDRA) operates in the Electromedical & Electrotherapeutic Apparatus industry.

What is NDRA's market cap?

ENDRA Life Sciences Inc. (NDRA) has a market capitalization of $7.06M as of 2026-06-30.

What exchange does NDRA trade on?

ENDRA Life Sciences Inc. (NDRA) trades on the Nasdaq.

Where is ENDRA Life Sciences Inc. incorporated?

ENDRA Life Sciences Inc. is incorporated in DE.